Close

Cerecor (CERC) Announces CERC-501 Phase 2 for Nicotine Withdrawal Missed Primary Endpoint

December 5, 2016 8:06 AM EST Send to a Friend
Cerecor Inc. (Nasdaq: CERC) announced top-line clinical results from its nicotine withdrawal Phase 2 clinical trial of CERC-501, an oral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login